Filtering by:
GeneticsShould You Get Genetic Testing for Cancer Risk?
Most cancers are not caused by inherited gene mutations. But if cancer runs in your family, you may want to consider genetic testing options.
FDA Approves Rozlytrek (Entrectinib) for Tumors With Certain Genetic Markers
The US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for adults and adolescents with tumors that test positive for NTRK gene changes, which can help cancerous tumors grow.
Not All Black Women in the United States Have the Same Level of Risk for Triple-Negative Breast Cancer
We’ve known for a while that triple-negative breast cancer is more common in black women in the United States, compared to other groups. The news is the prevalence varies significantly depending on where these women were born. American Cancer Society (ACS) researchers found that among black women, those born in the US and Western Africa were diagnosed more often with triple-negative breast cancer than women born in East Africa. The authors published their findings in Cancer, an ACS peer-reviewed journal.
Explore Your Family Cancer History
Protect your health by learning more about your family’s history of cancer and other health problems. Then find out what you can do to help lower your risk. Get the tips.
Colon and Endometrial Cancer Survivor Speaks Out About Lynch Syndrome
Jill Chang says she always knew she might get cancer some day. It seemed to run in the family. But she never dreamed she’d be diagnosed with cancer at age 30.
Year in Review: Cancer Research Insights from 2018
Read highlights about American Cancer Society research from 2018.
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
Study: New Genes Linked With Triple Negative Breast Cancer
We've known that mutations in the BRCA1 and BRCA2 genes are linked with an increased risk for breast cancer. Now we know about 5 other genes associated with a high risk for triple negative breast cancer (TNBC) thanks to a study by former American Cancer Society grant recipient, Fergus J. Couch, PhD. Knowing these genes can help doctors improve the screening process for women who have a personal or family history of breast or ovarian cancer. Identifying them also allows new treatments for TNBC to be tested.
